Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Maintains Buy on FormFactor, Lowers Price Target to $42

Citigroup analyst Amanda Scarnati maintains FormFactor (NASDAQ:FORM) with a Buy and lowers the price target from $45 to $42.
byBenzinga Newsdesk
July 29, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Citigroup analyst Amanda Scarnati maintains FormFactor (NASDAQ:FORM) with a Buy and lowers the price target from $45 to $42.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Candel Therapeutics Announces Oral Presentation During The 5th Glioblastoma Drug Development Summit With Update On Phase 1b Clinical Trial Of CAN-3110 In Recurrent High-Grade Glioma; Expects To Initiate Investigational New Drug-Enabling Work In A Secon…

By Benzinga Newsdesk
March 28, 4:17 PM
The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial. The serial procedures were well tolerated without observed dose-limiting toxicity. A second

CADL